In a collaborative effort, the JRC and three European partner organisations gathered lacking knowledge necessary to develop predictive in vitro tests that can identify the risk for the development of cumulative dose-dependent cardiotoxicity of cancer patients treated with anthracyclines.
Further information: Assessing drug-induced cardiotoxicity in vitro